The gut-liver axis as a target of liver disease management.
作者信息
Mandato Claudia, Delli Bovi Anna Pia, Vajro Pietro
机构信息
Department of Pediatrics, AORN "Santobono-Pausilipon", Naples, Italy.
Pediatrics, Department of Medicine and Surgery University of Salerno, Salerno, Italy.
出版信息
Hepatobiliary Surg Nutr. 2021 Jan;10(1):100-102. doi: 10.21037/hbsn.2020.03.27.
Abstract
摘要
相似文献
1
The gut-liver axis as a target of liver disease management.肠-肝轴作为肝病管理的靶点。
Hepatobiliary Surg Nutr. 2021 Jan;10(1):100-102. doi: 10.21037/hbsn.2020.03.27.
2
Targeting the gut-liver axis in liver disease.针对肝脏疾病的肠-肝轴。
J Hepatol. 2017 Nov;67(5):1084-1103. doi: 10.1016/j.jhep.2017.05.007. Epub 2017 May 16.
3
Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.肠-肝轴、肠道微生物群及其在肝脏疾病治疗中的调控：文献综述。
Int J Mol Sci. 2019 Jan 17;20(2):395. doi: 10.3390/ijms20020395.
4
Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.肝硬化中的肠-肝轴：如何应对肠道渗漏和内毒素血症。
World J Hepatol. 2015 Mar 27;7(3):425-42. doi: 10.4254/wjh.v7.i3.425.
5
The gut-liver-kidney axis: Novel regulator of fatty liver associated chronic kidney disease.肠-肝-肾轴：脂肪性肝病相关慢性肾脏病的新型调节因子。
Pharmacol Res. 2020 Feb;152:104617. doi: 10.1016/j.phrs.2019.104617. Epub 2019 Dec 24.
6
[Mechanism of gut-microbiota-liver axis in the pathogenesis of intestinal failure-associated liver disease].[肠道菌群-肝脏轴在肠衰竭相关肝病发病机制中的作用机制]
Zhonghua Wei Chang Wai Ke Za Zhi. 2021 Jan 25;24(1):94-100. doi: 10.3760/cma.j.cn.441530-20201009-00550.
7
The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.基于肠-肝轴的分子和机制见解：改善非酒精性脂肪性肝病（NAFLD）的营养靶点。
Int J Mol Sci. 2020 Apr 26;21(9):3066. doi: 10.3390/ijms21093066.
8
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH.肠-胰-肝轴作为治疗非酒精性脂肪性肝病/非酒精性脂肪性肝炎的靶点。
Int J Mol Sci. 2020 Aug 13;21(16):5820. doi: 10.3390/ijms21165820.
9
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群：非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.
10
Gut microbial dysbiosis associates hepatocellular carcinoma via the gut-liver axis.肠道微生物失调通过肠-肝轴与肝细胞癌相关。
Hepatobiliary Pancreat Dis Int. 2019 Feb;18(1):19-27. doi: 10.1016/j.hbpd.2018.11.002. Epub 2018 Nov 22.
引用本文的文献
1
Liver-draining portal lymph node responds to enteric nematode infection by generating highly parasite-specific follicular T helper and B cell responses.引流肝脏的门静脉淋巴结通过产生高度寄生虫特异性的滤泡辅助性T细胞和B细胞反应来应对肠道线虫感染。
Front Immunol. 2025 Feb 28;16:1483274. doi: 10.3389/fimmu.2025.1483274. eCollection 2025.
2
3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation.利用粪便微生物群移植在严重酒精性肝炎治疗中进行以精准医学为导向的创新。
EPMA J. 2024 Oct 31;15(4):677-692. doi: 10.1007/s13167-024-00381-5. eCollection 2024 Dec.
3
Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy.肠道微生物群、胰高血糖素样肽受体激动剂与营养的相互作用：代谢功能障碍相关脂肪性肝病治疗的新前沿。
World J Gastroenterol. 2024 Nov 21;30(43):4682-4688. doi: 10.3748/wjg.v30.i43.4682.
4
Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives.儿童代谢（功能）相关脂肪性肝病：当前认识与未来展望。
Hepatol Int. 2024 Oct;18(Suppl 2):873-883. doi: 10.1007/s12072-024-10691-5. Epub 2024 Jun 16.
5
Reasons why treatment of metabolic dysfunction-associated steatotic liver disease may benefit from targeting the gut-liver axis as well.治疗代谢功能障碍相关脂肪性肝病也可能从靶向肠-肝轴中获益的原因。
United European Gastroenterol J. 2024 May;12(4):528-529. doi: 10.1002/ueg2.12558. Epub 2024 Mar 27.
6
Multiple Sclerosis-Related Dietary and Nutritional Issues: An Updated Scoping Review with a Focus on Pediatrics.多发性硬化症相关的饮食和营养问题：一项以儿科为重点的最新范围综述
Children (Basel). 2023 Jun 7;10(6):1022. doi: 10.3390/children10061022.
7
Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.免疫相关胆管疾病复杂背景的若干方面——批判性综述。
Nutrients. 2023 Feb 2;15(3):760. doi: 10.3390/nu15030760.
8
Brain-gut-liver axis: Chronic psychological stress promotes liver injury and fibrosis gut in rats.脑-肠-肝轴：慢性心理应激促进大鼠肝损伤和纤维化。
Front Cell Infect Microbiol. 2022 Dec 12;12:1040749. doi: 10.3389/fcimb.2022.1040749. eCollection 2022.
9
Insight into the gut microbiome dysbiosis in patients with liver failure after extended-hepatectomy.扩大肝切除术后肝衰竭患者肠道微生物群失调的研究
Ann Transl Med. 2022 Nov;10(21):1186. doi: 10.21037/atm-22-3278.
10
Antibiotics and probiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and a meta-analysis.抗生素和益生菌对肝硬化肝静脉压力梯度的影响：系统评价和荟萃分析。
PLoS One. 2022 Aug 30;17(8):e0273231. doi: 10.1371/journal.pone.0273231. eCollection 2022.
本文引用的文献
1
Targeted Approaches for In Situ Gut Microbiome Manipulation.靶向肠道微生物组原位操作方法。
JPEN J Parenter Enteral Nutr. 2020 May;44(4):581-588. doi: 10.1002/jpen.1779. Epub 2020 Feb 6.
2
Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis.肝脏疾病和肝硬化中的微生物群变化及肠道微生物群移植
J Hepatol. 2020 May;72(5):1003-1027. doi: 10.1016/j.jhep.2020.01.017. Epub 2020 Jan 28.
3
The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials.地中海饮食对非酒精性脂肪肝患者代谢参数的影响：随机对照试验的系统评价。
Clin Nutr ESPEN. 2020 Feb;35:40-46. doi: 10.1016/j.clnesp.2019.10.008. Epub 2019 Nov 15.
4
Gut microbiome in HCC - Mechanisms, diagnosis and therapy.肝癌中的肠道微生物组：机制、诊断与治疗。
J Hepatol. 2020 Feb;72(2):230-238. doi: 10.1016/j.jhep.2019.08.016.
5
Akkermansia muciniphila Prevents Fatty Liver Disease, Decreases Serum Triglycerides, and Maintains Gut Homeostasis.阿克曼氏菌可预防脂肪肝疾病，降低血清甘油三酯，并维持肠道内环境稳定。
Appl Environ Microbiol. 2020 Mar 18;86(7). doi: 10.1128/AEM.03004-19.
6
Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.非酒精性脂肪性肝病和酒精性肝病中的肠道微生物群：当前概念与展望
Hepatol Res. 2020 Apr;50(4):407-418. doi: 10.1111/hepr.13473. Epub 2020 Jan 13.
7
The gut-liver axis in liver disease: Pathophysiological basis for therapy.肝脏疾病中的肠-肝轴：治疗的病理生理学基础。
J Hepatol. 2020 Mar;72(3):558-577. doi: 10.1016/j.jhep.2019.10.003. Epub 2019 Oct 14.
8
Gut and oral microbiota in autoimmune liver disease.自身免疫性肝病中的肠道和口腔微生物群
Fukushima J Med Sci. 2020 Jan 9;65(3):71-75. doi: 10.5387/fms.2019-21. Epub 2019 Sep 27.
9
Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development.肠道微生物群驱动的肠道血管屏障破坏是非酒精性脂肪性肝炎发展的前提。
J Hepatol. 2019 Dec;71(6):1216-1228. doi: 10.1016/j.jhep.2019.08.005. Epub 2019 Aug 13.
10
Next generation probiotics in disease amelioration.改善疾病的新一代益生菌。
J Food Drug Anal. 2019 Jul;27(3):615-622. doi: 10.1016/j.jfda.2018.12.011. Epub 2019 Feb 2.
Zotero 插件